Strides Arcolab Ltd. said its wholly-owned subsidiary Onco Therapies Ltd., obtained US FDA approvals for Methotrexate Injection USP 25mg/ mL packaged in 1 gm/40 m, 50mg/2 mL, 100mg/ 4mL, 200mg/8 mL and 250mg/10 mL single dose vials - preservative-free.
Methotrexate is part of the Oncology portfolio licensed to Pfizer in January 2010 for the US market. The company said it would launch the product shortly.
Methotrexate is a chemotherapy drug used either alone or in combination with other agents. It is used as a treatment for some autoimmune diseases including rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus and Crohn's disease, to name a few.
Methotrexate is amongst the products in the drug shortage list of US FDA, the company said.
As per IMS data, the US market for generic Methotrexate is around $13 million.
At the BSE, Stride Arcolab closed Friday's trading at Rs.580, down 1.62 percent from the previous close.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org